Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
| Status: | Completed |
|---|---|
| Conditions: | Other Indications |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2008 |
| End Date: | December 2012 |
Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading
to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic
dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only
and does not alter the course of disease.
Although the cause of MSA remains unclear, there is evidence of presence of common
neuroinflammatory mechanisms in the MSA brains including activation of microglia and
production of toxic cytokines. This research protocol is based on hypothesis that the MSA
progression can be altered by blocking the neuroinflammatory activity.
This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains
antibodies derived from human plasma which can block the inflammatory responses in the brain
that can lead to loss of brain cells.
to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic
dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only
and does not alter the course of disease.
Although the cause of MSA remains unclear, there is evidence of presence of common
neuroinflammatory mechanisms in the MSA brains including activation of microglia and
production of toxic cytokines. This research protocol is based on hypothesis that the MSA
progression can be altered by blocking the neuroinflammatory activity.
This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains
antibodies derived from human plasma which can block the inflammatory responses in the brain
that can lead to loss of brain cells.
Inclusion Criteria:
1. Male or female older than 17 years.
2. Clinical diagnosis of probable multiple system atrophy
3. Provide written informed consent to participate in the study
4. Understand that they may withdraw their consent at any time
Exclusion Criteria:
1. Women who are pregnant or lactating
2. In the investigator's opinion, have any other significant systemic, hepatic, cardiac
or renal illness.
3. In the investigator's opinion, the subjects are significantly dehydrated, as
determined by clinical evaluation including measurement of skin turgor, blood urea
nitrogen and creatinine values.
We found this trial at
1
site
Univ of Massachusetts Med School As the commonwealth's only public medical school, we take seriously...
Click here to add this to my saved trials
